News about Drug Discovery & Development

Biogen and Stoke Therapeutics to Develop and Commercialize Zorevunersen

Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome.

Drug Discovery & Development | 20/02/2025 | By Aishwarya |  364

Innocan Pharma Secures its First Patent in India for its Liposomal CBD Injection

This granted patent protects Innocan's synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), designed for precise dosing and sustained release of Synthetic CBD into the bloodstream.

Drug Discovery & Development | 19/02/2025 | By Aishwarya |  473

Glenmark Pharmaceuticals Inc., USA Launches Clindamycin Phosphate Foam, 1 percent

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1 percent.

Drug Discovery & Development | 12/02/2025 | By Manvi |  253

Hoth Therapeutics Collaborates with OnTargetx R&D Inc. to Advance Research for its Cancer-Fighting Therapeutic 'HT-KIT'

This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step in the preclinical development of HT-KIT.

Drug Discovery & Development | 11/02/2025 | By Manvi |  374

Cosmo and Glenmark Receive UK MHRA Approval of Winlevi for Treatment of Acne

Winlevi® is a topical treatment for acne vulgaris in patients aged 12 years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.

Drug Discovery & Development | 10/02/2025 | By Aishwarya |  557

Jupiter Neurosciences Signs JOTROL Manufacturing Agreement with Catalent

Under the terms of the agreement, Catalent will manufacture clinical batches of JOTROL, Jupiter’s proprietary resveratrol-based therapeutic, using an optimized softgel formulation.

Drug Discovery & Development | 04/02/2025 | By Aishwarya |  374

Akums Combines Two Potent Diabetes Medicines for Enhanced Treatment Efficacy

Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, aids in eliminating excess glucose via urine while delivering additional benefits such as improved cardiovascular and renal outcomes, along with better weight management.

Drug Discovery & Development | 03/02/2025 | By Aishwarya |  661

Kenox Pharmaceuticals Enhances Capabilities to Boost Drug Development

Kenox Pharmaceuticals Inc has expanded its capabilities with small-scale non-sterile GMP facilities to support GLP pre-clinical studies, reinforcing its commitment to accelerating the development of innovative Orally Inhaled and Nasal Drug Products (OINDPs).

Drug Discovery & Development | 29/01/2025 | By Manvi |  349

FDA Grants Priority Review to Merck's Application for 'WELIREG'

Merck announced the US FDA has accepted for priority review a supplemental new drug application (sNDA) seeking approval of WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult and and pediatric patients (12 years and older).

Drug Discovery & Development | 27/01/2025 | By Manvi |  202

Glenmark Pharmaceuticals Unveils Generic Anticoagulant Injectable Emulsion

Glenmark's Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL of Hospira, Inc., ANDA 087955.

Drug Discovery & Development | 24/01/2025 | By Aishwarya |  638